Clinical trials: Hepatitis A
Hepatitis C
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
- Trial name
- NCT00821587
- Testing
- Cyclosporine, Tacrolimus
- Volunteers
- 39 people
- Sponsor
- University of Florida
HIV Infections
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa).
- Trial name
- NCT00625404
- Testing
- Truvada
- Where
- 4 sites in Kenya, South Africa and 1 more
- Volunteers
- 2,120 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatitis C, Chronic
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
This is a non-randomized, open-label, single-dose study to evaluate the pharmacokinetics (PK) of uprifosbuvir (MK-3682), the M5 and M6 metabolites of uprifosbuvir, and ruzasvir (MK-8408), in participants with moderate hepatic…
- Trial name
- NCT02666352
- Testing
- Uprifosbuvir, Ruzasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Viral, Chronic Kidney Disease stage3
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may safely be used for the elderly patients with renal dysfunction.
- Trial name
- NCT03144635
- Testing
- Grazoprevir plus Elbasvir
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Kyushu University
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to…
- Trial name
- STEALTHC-2 (NCT00495391)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Romark Laboratories L.C.
Hepatitis A
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a varicella (chickenpox) vaccine in children as young…
- Trial name
- NCT00197015
- Testing
- Havrix®, M-M-R®II, VARIVAX®
- Where
- 42 sites in United States
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
Hepatitis B, Vertical Transmission of Infectious Disease
Arresting Vertical Transmission of Hepatitis B Virus
The purpose of this pilot study is to demonstrate the feasibility of adding HBV screening and treatment of pregnant women to the existing HIV PMTCT platform in order to prevent mother-to-child transmission of hepatitis B virus.
- Trial name
- AVERT-HBV (NCT03567382)
- Testing
- Tenofovir Disoproxil Fumarate, Monovalent HBV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 179 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Hepatitis C
The SIM-SOF Trial for Hepatitis C
Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without…
- Trial name
- NCT02168361
- Testing
- Pegylated Interferon alfa-2b, Simeprevir, Ribavirin
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Center For Hepatitis C, Atlanta, GA
HIV, Hepatitis C
Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)
This study will evaluate the referral to harm reduction services (HRS) including syringe services, naloxone overdose prevention, substance use treatment referral, HIV, HCV, and STD testing and referral and linkage to care through…
- Conditions
- HIV, Hepatitis C, Opioid-use Disorder, Injection Drug Use
- Trial name
- ETHIC (NCT04427202)
- Testing
- Referral to harm reduction services
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- University of Chicago
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus…
- Trial name
- NCT04398134
- Testing
- ABI-H2158, Entecavir (ETV)
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 88 people
- Sponsor
- Assembly Biosciences
Chronic Hepatitis B
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
The purpose of this study is to evaluate the efficacy and safety following the Roadmap Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg negative CHB patients.
- Trial name
- NCT01379508
- Testing
- telbivudine, tenofovir disoproxil fumarate
- Where
- 34 sites in Austria, Bulgaria and 6 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
The presence of persistent inadequate or suboptimal virologic response is a strong risk factor for viral resistance and breakthrough and also for disease progression of chronic hepatitis B, and thus, a change in therapy is…
- Trial name
- CAESAR (NCT01023217)
- Testing
- Adefovir, Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
Chronic Hepatitis c, Cirrhosis, Liver
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to…
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Trial name
- HALT-C (NCT00006164)
- Testing
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Where
- 11 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis
- Trial name
- NCT01995071
- Testing
- ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333
- Volunteers
- 89 people
- Sponsor
- AbbVie
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.